作者
Neal A Halsey, Jacqueline S Coberly, Julio Desormeaux, Phyllis Losikoff, Joan Atkinson, Lawrence H Moulton, Mireil Contave, Michael Johnson, Homer Davis, Lawrence Geiter, Erica Johnson, Robin Huebner, Reginald Boulos, Richard E Chaisson
发表日期
1998/3/14
期刊
The lancet
卷号
351
期号
9105
页码范围
786-792
出版商
Elsevier
简介
Background
Tuberculosis is a common complication of HIV-1 infection, especially in developing countries. Practical and effective chemoprophylaxis regimens for HIV-1-related tuberculosis are needed. Our aim was to test the efficacy of isoniazid versus rifampicin with pyrazinamide for prevention of tuberculosis in HIV-1-positive individuals.
Methods
We compared the efficacy of 6 months of isoniazid with 2 months of rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1-seropositive individuals. Eligible participants were aged 16–77 years, HIV-1 seropositive, had a positive purified-protein derivative (PPD) skin test reaction of at least 5 mm, and had a normal chest radiograph. Participants were randomly assigned partially supervised twice weekly isoniazid for 24 weeks or twice weekly rifampicin and pyrazinamide for 8 weeks. Participants were followed up for up to 4 years for the development of …
引用总数
学术搜索中的文章
NA Halsey, JS Coberly, J Desormeaux, P Losikoff… - The lancet, 1998